ISO 10993 existing data | Materials Metric

What Is ISO 10993 Existing Data — and Why Does It Matter?

ISO 10993 existing data refers to previously generated chemical, toxicological, and clinical information that manufacturers can use to satisfy biocompatibility evaluation requirements without conducting new animal or in vitro tests. At Materials Metric, we help device teams systematically identify, assess, and document this data to streamline regulatory submissions and reduce unnecessary testing burdens.

Medical device biocompatibility assessment has historically relied on extensive new testing. However, the ISO 10993 series — particularly ISO 10993-18 Chemical Characterization — now explicitly encourages a data-driven approach. Regulators, including the FDA, expect manufacturers to exhaust existing information before ordering fresh studies. Consequently, understanding how to leverage ISO 10993 existing data has become a core compliance skill.

Furthermore, the shift toward a risk-based framework means that well-documented existing data can replace or significantly reduce new in vivo testing. This benefits patient safety by accelerating device reviews. It also reduces development costs and animal use, aligning with the 3Rs principles of Replace, Reduce, and Refine.

Key Takeaways

ISO 10993 existing data includes prior chemical, toxicological, clinical, and literature-based information that supports biocompatibility evaluation.

Regulators expect manufacturers to evaluate existing data before ordering new animal or in vitro tests.

ISO 10993-18 and ISO 10993-1 provide the framework for identifying, assessing, and documenting existing data gaps.

A structured data gap analysis determines which, if any, additional tests remain necessary.

Chemical characterization results from techniques such as GC-MS Analysis and HPLC Analysis often form the backbone of an existing-data package.

Partnering with an experienced laboratory accelerates data review and gap closure.

ISO 10993 existing data: Any previously generated chemical characterization, toxicological, clinical, literature-derived, or post-market information that a medical device manufacturer uses — within an ISO 10993-compliant biological evaluation — to demonstrate biocompatibility without conducting new tests.

Key fact: ISO 10993-1 identifies existing data review as the first required step in every biological evaluation plan, making it the regulatory starting point — not an optional shortcut.

What Types of ISO 10993 Existing Data Can Manufacturers Use?

Manufacturers can draw from a wide range of sources when building an existing-data package. Understanding the categories helps teams conduct a thorough and defensible review. Moreover, recognizing what counts as valid existing data prevents teams from overlooking valuable information they already hold.

Chemical and Material Composition Data

Material composition data is often the most immediate source of existing information. Suppliers frequently provide ingredient lists, material safety data sheets (SDS), and certificates of conformance (CoC). These documents identify chemical constituents and often reference established toxicological profiles.

However, supplier declarations alone rarely satisfy ISO 10993-18 requirements. Teams must correlate composition data with toxicological thresholds such as the Tolerable Intake (TI) or the Threshold of Toxicological Concern (TTC). Therefore, having an analytical chemistry partner review these documents against regulatory limits adds significant value. Our Chemical & Elemental Characterization service supports exactly this review process.

Prior Chemical Characterization Reports

Previously conducted chemical characterization studies represent high-quality existing data. Specifically, reports generated under ISO 10993-18 for similar or identical materials can often be leveraged directly. Analytical data from methods like FTIR Analysis, XRF Analysis, and NMR Spectroscopy can confirm chemical identity and support risk assessments.

Importantly, these reports must demonstrate relevance to the device under evaluation. Factors such as the same material lot, processing conditions, and patient contact duration all affect whether prior data transfers directly. Our article on ISO 10993-18 compliance explores how to structure these assessments in detail.

Published Literature and Toxicological Databases

Peer-reviewed literature and established toxicological databases provide another powerful category of existing data. Sources such as PubMed Central offer access to thousands of studies on polymer extractables, metal ions, and processing residuals. Similarly, databases like TOXNET, IRIS, and ECHA provide regulatory toxicology values directly applicable to ISO 10993 risk assessments.

Furthermore, ISO 10993-17 provides a systematic method for deriving tolerable exposure levels from published data. Teams should therefore document their literature search strategy, including the databases searched, keywords used, and inclusion or exclusion criteria. This documentation demonstrates due diligence to reviewers.

Clinical and Post-Market Surveillance Data

For devices already on the market, post-market surveillance (PMS) data and clinical history constitute valuable existing information. A long and uneventful clinical record for a materially equivalent device can support a presumption of biocompatibility. Notably, regulators increasingly expect manufacturers to incorporate PMS data into biological evaluations rather than treating it as separate documentation.

Similarly, adverse event reports — even negative findings — provide evidence for the risk assessment. Our team at Scientific & Technical Consulting can help interpret PMS records within the ISO 10993-1 framework.

How Does ISO 10993-1 Define the Existing Data Review Process?

ISO 10993-1 establishes the overarching framework for biological evaluation. It requires manufacturers to develop a Biological Evaluation Plan (BEP) and a corresponding Biological Evaluation Report (BER). At the heart of both documents lies the review of ISO 10993 existing data before any testing decision.

The Biological Evaluation Plan and Existing Data

The BEP must explicitly describe how the manufacturer will identify, gather, and assess existing data. It should specify the sources of information, the risk assessment methods, and the criteria for determining data adequacy. In addition, the BEP must outline what new tests — if any — will be triggered by data gaps.

Consequently, the BEP is not merely an administrative document. It functions as a strategic roadmap that determines testing scope and budget. A well-constructed BEP centered on ISO 10993 existing data can legitimately eliminate entire test categories. Our related article on FDA biocompatibility deficiencies highlights what happens when BEPs fail to do this adequately.

Conducting a Structured Data Gap Analysis

A data gap analysis compares available existing data against the endpoints required by ISO 10993-1 for a given device category. The analysis identifies areas where data is sufficient and areas where new testing remains necessary. Therefore, it forms the bridge between the existing-data review and the testing plan.

The following table summarizes the ISO 10993-1 biological evaluation endpoints and the types of existing data that commonly address each one.

Biological Endpoint	Common Existing Data Sources	Relevant Analytical Method
Cytotoxicity	Published polymer safety data, prior test reports	Biocompatibility & Toxicity Testing
Sensitization	Chemical composition, REACH/SVHC data	Chemical Purity & Contaminant Screening
Genotoxicity	Literature, ECHA, IRIS toxicology values	GC-MS Analysis
Systemic Toxicity	ISO 10993-17 TI derivation, clinical data	HPLC Analysis
Elemental Impurities	ICP-MS supplier data, USP <232> reports	Chemical & Elemental Characterization
Pyrogenicity	Material history, prior endotoxin data	Wet Chemistry & Classical Analytical Methods
Hemocompatibility	Published hemocompatibility profiles for material class	Biocompatibility & Toxicity Testing

Documenting Data Adequacy and Justifying Waivers

When existing data fully addresses a biological endpoint, the manufacturer must formally document why no new test is needed. This justification — sometimes called a test waiver — must be scientifically rigorous and explicitly referenced in the BER. Reviewers at the FDA and notified bodies scrutinize these waivers closely.

Moreover, the waiver must account for device-specific factors such as surface contact area, contact duration, and patient population. For example, a short-term skin-contact device may rely on existing dermal sensitization literature far more readily than a long-term implant can. Consequently, the quality of the waiver argument directly determines whether the regulator accepts it or requests additional studies.

Quick note: A test waiver based on ISO 10993 existing data is not simply a statement that “no testing was done.” It must demonstrate — with cited data and risk calculations — that the absence of new testing is scientifically justified and protective of patient safety.

How Do Chemical Characterization Methods Support Existing Data Packages?

Chemical characterization plays a central role in building credible ISO 10993 existing data packages. Analytical methods identify and quantify extractable and leachable chemicals from device materials. These results feed directly into toxicological risk assessments that determine whether patient exposure remains below safe thresholds.

Selecting the Right Analytical Techniques

No single analytical technique captures every relevant chemical. Therefore, a well-designed characterization strategy typically combines orthogonal methods. For volatile and semi-volatile organics, GC-MS Analysis delivers high sensitivity and broad compound coverage. For non-volatile organics and polymeric additives, HPLC Analysis provides complementary separation and quantification.

In addition, elemental impurities require dedicated inorganic analysis. Techniques such as XRF Analysis screen for heavy metals across a broad elemental range. Meanwhile, XPS Analysis characterizes surface chemistry with nanometer-scale depth resolution. Together, these methods satisfy the chemical characterization requirements of ISO 10993-18.

Connecting Characterization Data to Toxicological Thresholds

Raw analytical results have limited regulatory value until they connect to patient exposure estimates and toxicological limits. Specifically, ISO 10993-17 requires that estimated daily doses of identified leachables compare against tolerable intake values. If every identified chemical falls below its threshold, the risk assessment supports a biocompatibility conclusion without additional in vivo testing.

Furthermore, the USP General Chapter <232> Elemental Impurities framework provides permitted daily exposure (PDE) values for a comprehensive list of elemental impurities. Cross-referencing ICP-MS or XRF results against these limits is a standard step in building defensible ISO 10993 existing data packages. Our Chemical & Analytical Testing team routinely integrates this cross-referencing into every characterization report.

Material Equivalency and Bridging Studies

A common and efficient strategy involves demonstrating that a new device material is chemically equivalent to a previously characterized material. When equivalency holds, the existing characterization data bridges directly to the new device without repeated testing. Our dedicated article on device material equivalency explains the criteria and documentation requirements in detail.

However, equivalency arguments must be rigorously supported. Minor changes in polymer grade, processing additives, or sterilization method can introduce new extractables that invalidate a direct comparison. Consequently, a targeted bridging study — using focused analytical methods such as Raman Spectroscopy or DSC Testing — may be necessary to confirm that the materials are truly comparable before the waiver stands.

How Can Manufacturers Strategically Leverage Existing Data to Reduce Testing?

Leveraging ISO 10993 existing data effectively requires a structured, prioritized approach. Teams that treat existing data as a compliance checkbox rather than a strategic asset routinely over-test and overspend. Moreover, regulators increasingly flag unnecessary testing as evidence of poor risk management discipline.

Building a Tiered Data Review Strategy

A tiered strategy starts with the lowest-effort, highest-yield data sources. Internal material files, prior characterization reports, and supplier documentation form the first tier. These sources require no new testing and often resolve multiple biological endpoints simultaneously.

The second tier draws on published literature, toxicological databases, and regulatory agency dossiers. For example, ECHA substance evaluations and FDA master access files frequently contain relevant safety data for common polymers and metals. Furthermore, cross-referencing these sources against device-specific contact conditions is straightforward and well-accepted by reviewers.

The third tier involves targeted gap-filling studies. Consequently, manufacturers only commission new analytical or biological tests when tiers one and two leave genuine, unresolvable data gaps. This discipline keeps total project cost and timeline under control without sacrificing submission quality.

Prioritizing High-Risk Chemical Entities

Not every chemical identified in a material composition list warrants equal scrutiny. Therefore, teams should prioritize substances with known genotoxic, carcinogenic, reproductive, or sensitizing hazard classifications. These high-concern chemicals demand robust existing data or, if absent, targeted new testing.

By contrast, well-characterized, low-toxicity processing aids with decades of safe use history can often close out quickly using published acceptable daily intake (ADI) values. Our Chemical Purity & Contaminant Screening service identifies and ranks these substances early in the evaluation process, ensuring teams focus resources where the risk is highest.

Integrating Existing Data Across Device Families

Manufacturers with broad device portfolios can leverage existing data across product families systematically. Specifically, a master characterization file for a polymer platform can support multiple device submissions that share the same base material. This platform approach dramatically reduces per-device evaluation costs.

However, each device application must still receive its own contact-specific risk assessment. Differences in surface area, sterilization method, and use duration all affect patient exposure estimates. Consequently, even a robust platform file requires device-level customization before it satisfies a regulator’s expectations fully.

What Advanced Analytical Techniques Strengthen Existing Data Packages?

When existing documentation leaves chemical gaps, targeted analytical testing generates new data efficiently. Selecting the right technique ensures that gap-filling studies produce results directly usable in ISO 10993 risk assessments. Furthermore, method selection should align with the chemical classes most likely to be present in the device material.

ICP-MS and ICP-OES for Elemental Impurities

Inductively coupled plasma mass spectrometry (ICP-MS) and optical emission spectrometry (ICP-OES) represent the gold standard for elemental impurity quantification. Both techniques detect metals and metalloids at parts-per-billion or parts-per-trillion concentrations. Additionally, their broad elemental coverage makes them ideal for screening against USP Elemental Impurities permitted daily exposure limits.

ICP-MS offers superior sensitivity for toxic metals such as arsenic, cadmium, and lead. Meanwhile, ICP-OES provides excellent precision for major and minor elemental constituents. Together, these techniques cover the full elemental panel required under ISO 10993-18 and relevant pharmacopoeial standards. Our Chemical & Elemental Characterization laboratory operates both platforms with validated methods.

Thermal and Surface Characterization Techniques

Structural and surface analysis methods add important dimensions to chemical characterization packages. XPS Analysis quantifies surface elemental composition and oxidation states within the outermost nanometers of a device surface. This capability is particularly valuable for implants and blood-contacting devices where surface chemistry drives biological response.

In addition, SEM Analysis reveals surface morphology, particulate contamination, and coating integrity at micrometer resolution. Similarly, XRD Analysis identifies crystalline phases in metallic and ceramic device components. Collectively, these surface techniques generate existing-data-quality outputs that support both chemical and physical biocompatibility arguments.

Organic Extractables Profiling

Comprehensive organic extractables profiling under ISO 10993-18 conditions generates data directly usable in risk assessments. Specifically, GC-MS Analysis and HPLC Analysis run in parallel cover volatile, semi-volatile, and non-volatile organic fractions. Results from these studies, once reported and archived, become reusable existing data for subsequent submissions.

Furthermore, NMR Spectroscopy provides structural confirmation of unknown extractables that GC-MS libraries cannot resolve definitively. Combining GC-MS with NMR increases chemical identification confidence and strengthens risk assessment defensibility. This multi-technique approach is recognized as best practice in current ISO 10993-18 guidance.

The following table compares key analytical techniques commonly used to generate ISO 10993 existing data for chemical characterization purposes.

Technique	Chemical Class Detected	Key Strength	ISO 10993-18 Role
GC-MS	Volatile / semi-volatile organics	Broad library screening	Extractables identification
HPLC	Non-volatile organics, additives	Quantification of additives	Leachables quantification
ICP-MS / ICP-OES	Elemental impurities	Sub-ppb detection limits	Elemental risk assessment
XPS	Surface elemental composition	Nanometer depth resolution	Surface chemistry characterization
NMR	Unknown organic structures	Definitive structural ID	Unknown extractables confirmation
FTIR	Polymers, functional groups	Rapid material identification	Material equivalency confirmation

What Quality Assurance Practices Ensure Defensible Existing Data Packages?

Generating and assembling existing data is only half the challenge. Ensuring that data meets regulatory quality standards is equally critical. Notably, regulators reject submissions not because data is absent, but because documentation, traceability, and method validation are insufficient.

Ensuring Method Validity and Traceability

All analytical data cited as existing data must derive from validated or at minimum well-characterized methods. Specifically, ISO 17025-accredited laboratories provide the strongest defensibility because accreditation confirms method performance on an independent basis. Our Method Development & Validation service ensures that every analytical method meets fit-for-purpose validation requirements under ISO 10993-18 and ICH Q2(R1).

Furthermore, full analytical traceability — sample identity, chain of custody, instrument calibration records, and reference standard certificates — must accompany every dataset. Reviewers at notified bodies and the FDA routinely request raw data and audit trails during technical file reviews. Consequently, laboratories that maintain complete electronic records significantly reduce the risk of information requests delaying submissions.

Structuring the Biological Evaluation Report

The Biological Evaluation Report (BER) is the primary regulatory deliverable that consolidates existing data, gap analysis results, and risk conclusions. Therefore, its structure and clarity directly determine submission success. Each endpoint section should cite specific data sources, state the risk calculation method, and conclude with a clear acceptability statement.

In addition, cross-referencing between the BEP and BER is essential. Regulators check that the BER executes what the BEP promised. Moreover, any deviations from the original plan must receive documented scientific justification. Our Scientific & Technical Consulting team assists clients in structuring BERs that satisfy both FDA and EU MDR requirements.

Keeping Existing Data Current Through Change Control

Existing data packages are not static documents. Material changes, new sterilization methods, or supplier substitutions can invalidate previously accepted conclusions. Therefore, manufacturers must integrate the biological evaluation into their design change control process.

For instance, a change in antioxidant grade within a polymer formulation may introduce a new extractable not captured in the original characterization. Consequently, a brief targeted study using FTIR Analysis or Raman Spectroscopy can confirm chemical equivalency before the change receives design history approval. Proactive change control prevents costly post-market data gaps from emerging during regulatory surveillance audits. Published research on analytical methodology verification, such as resources available through ScienceDirect, supports best practices in this area.

Quick note: Existing data packages tied to specific material lot numbers or supplier specifications become partially or fully invalid when those specifications change — even when the change appears minor. Always re-evaluate scope after any formulation or process update.

Frequently Asked Questions About Leveraging Existing Data

What makes ISO 10993 existing data acceptable to regulators?

Existing data must be relevant, reliable, and traceable. Regulators require that each data source clearly applies to the device material, contact type, and duration under evaluation. Furthermore, the data must derive from validated methods, credible publications, or recognized databases. Unsupported claims or undated supplier letters rarely satisfy technical file reviewers.

Can prior test reports from a different device support a new submission?

Yes, under specific conditions. The prior device must use the same or demonstrably equivalent materials, processed identically, and sterilized by the same method. Additionally, contact classification and duration must be comparable. Without a formal material equivalency argument documented in the BEP, reviewers will likely reject the cross-reference. Our article on device material equivalency covers the documentation requirements thoroughly.

How recent must existing data be to remain valid?

ISO 10993-1 does not specify a fixed expiry period for existing data. However, data generated under superseded test standards or outdated chemical characterization protocols may require supplementation. Moreover, significant changes in manufacturing, supplier, or sterilization after the original data generation date can reduce its applicability. Reviewers typically expect manufacturers to assess data currency explicitly within the BER.

Does chemical characterization always replace biological testing?

Not always. Chemical characterization supports risk-based justifications for waiving certain tests, but it does not automatically replace all biological endpoints. Specifically, endpoints such as hemocompatibility for blood-contacting devices or specific implant-related endpoints may still require dedicated biological studies when chemical data alone cannot establish safety. Therefore, each endpoint needs individual justification regardless of characterization data quality.

How does the FDA view existing data in 510(k) submissions?

The FDA’s 2016 biocompatibility guidance explicitly endorses the use of existing data to address biological evaluation endpoints in 510(k) submissions. Consequently, FDA reviewers expect to see a systematic existing-data review documented in the submission. Importantly, the FDA also reserves the right to request additional studies if existing data fails to address device-specific risks adequately. Our article on FDA biocompatibility deficiencies details the most common gaps that trigger additional information requests.

What role does a contract testing laboratory play in existing data evaluation?

A qualified contract laboratory contributes in several important ways. Specifically, it reviews and assesses existing documentation for technical adequacy, identifies analytical gaps, designs targeted gap-filling studies, and generates defensible data under validated conditions. Furthermore, experienced laboratories help translate raw analytical results into risk assessment language that BERs require. Our Chemical & Analytical Testing and Biocompatibility & Toxicity Testing teams provide this full-spectrum support.

Conclusion

Effectively leveraging ISO 10993 existing data is one of the most powerful strategies available to medical device manufacturers. A disciplined, tiered approach to data review reduces unnecessary testing, controls development costs, and accelerates regulatory timelines. Moreover, it demonstrates to regulators that a manufacturer understands and applies risk-based principles correctly — a quality signal that builds submission credibility.

The process demands systematic documentation, validated analytical support, and rigorous toxicological reasoning. Therefore, partnering with a laboratory that understands both the analytical and regulatory dimensions of ISO 10993 is essential. At Materials Metric, our integrated capabilities — from Chemical & Elemental Characterization and Method Development & Validation to Scientific & Technical Consulting — support every stage of the existing data evaluation process.

Furthermore, our team brings direct experience with FDA 510(k) and EU MDR submissions, helping clients build packages that withstand regulatory scrutiny the first time. We help you identify what you already have, close the gaps efficiently, and document everything to the standard regulators expect.

If your team needs support building or reviewing an ISO 10993 existing data package, we encourage you to contact Materials Metric today to discuss your specific device, materials, and regulatory pathway. Our experts are ready to help you move forward with confidence and clarity.